UiPath (NYSE:PATH) PT Raised to $18.00

UiPath (NYSE:PATH) had its target price increased by stock analysts at Mizuho from $16.00 to $18.00 in a report issued on Thursday, MarketBeat Ratings reports. The firm presently has a “neutral” rating on the healthcare company’s stock. Mizuho’s price target would suggest a potential downside of 2.70% from the company’s previous close.

Several other research analysts also recently weighed in on the company. Wells Fargo & Company downgraded UiPath from an “overweight” rating to an “equal weight” rating and set a $20.00 price target for the company. in a report on Friday, June 9th. Bank of America boosted their price target on UiPath from $20.00 to $22.00 in a report on Thursday. Barclays boosted their price target on UiPath from $16.00 to $18.00 in a report on Thursday. Finally, BMO Capital Markets lowered their price objective on shares of UiPath from $20.00 to $18.00 in a research note on Thursday, May 25th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $19.84.

UiPath Price Performance

Shares of UiPath stock opened at $18.50 on Thursday. UiPath has a 1 year low of $10.40 and a 1 year high of $19.94. The company has a market capitalization of $10.38 billion, a P/E ratio of -57.66 and a beta of 0.69. The business has a 50 day moving average price of $16.45 and a 200 day moving average price of $16.10.

UiPath (NYSE:PATH) last issued its quarterly earnings results on Wednesday, September 6th. The healthcare company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $287.31 million during the quarter, compared to the consensus estimate of $281.48 million. UiPath had a negative return on equity of 7.56% and a negative net margin of 15.47%. UiPath’s revenue was up 18.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.18) EPS. As a group, research analysts expect that UiPath will post -0.28 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $18.42, for a total transaction of $736,800.00. Following the completion of the sale, the chief financial officer now directly owns 1,544,341 shares of the company’s stock, valued at approximately $28,446,761.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $18.42, for a total transaction of $736,800.00. Following the completion of the sale, the chief financial officer now directly owns 1,544,341 shares of the company’s stock, valued at approximately $28,446,761.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rich Wong sold 56,549 shares of the company’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $17.97, for a total transaction of $1,016,185.53. Following the sale, the director now directly owns 879,693 shares of the company’s stock, valued at $15,808,083.21. The disclosure for this sale can be found here. In the last three months, insiders sold 220,000 shares of company stock valued at $3,892,635. Company insiders own 31.03% of the company’s stock.

Hedge Funds Weigh In On UiPath

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning boosted its position in UiPath by 7.0% in the 2nd quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after buying an additional 666 shares during the last quarter. Voya Investment Management LLC boosted its position in UiPath by 1.2% in the 4th quarter. Voya Investment Management LLC now owns 58,567 shares of the healthcare company’s stock valued at $744,000 after buying an additional 719 shares during the last quarter. SRS Capital Advisors Inc. boosted its position in UiPath by 20.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,208 shares of the healthcare company’s stock valued at $66,000 after buying an additional 884 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in UiPath by 24.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 5,705 shares of the healthcare company’s stock valued at $100,000 after buying an additional 1,120 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in shares of UiPath by 0.7% in the 1st quarter. Treasurer of the State of North Carolina now owns 164,798 shares of the healthcare company’s stock valued at $2,894,000 after purchasing an additional 1,170 shares in the last quarter. 59.04% of the stock is owned by hedge funds and other institutional investors.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.